Inactive
Notice ID:36E79723R0004
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79723R0004 for an unrestrictive procurement for Orexin Inhibitors, for the Department of Vete...
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79723R0004 for an unrestrictive procurement for Orexin Inhibitors, for the Department of Veterans Affairs (VA), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s Pharmaceutical Prime Vendor Program. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. Solicitation # 36E79723R0004 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about December 14, 2022, with a tentative closing date of December 28, 2022. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: https://sam.gov/content/home . No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Kenneth Lay Questions can be e-mailed to: Kenneth.Lay@va.gov. The estimated annual requirements are as follows: DESCRIPTION TOTAL ESTIMATED ANNUAL USAGE (TABLETS) *OREXIN INHIBITORS CLASS ARE AS FOLLOWS: 110,610 DARIDOREXANT or LEMBOREXANT or SUVOREXANT * Offerors must propose all strengths and package sizes commercially available. This will not affect the number of tablets listed in the usage requirements.
